NCLEX Review Guide: Kidney Transplantation

Overview of Kidney Transplantation

• Kidney transplantation is the surgical placement of a healthy kidney from a donor into a recipient with end-stage renal disease (ESRD). This procedure is considered when the patient's kidneys have failed to function at less than 15% of normal capacity, typically after conservative management and dialysis options have been explored.
• Transplantation offers improved quality of life compared to dialysis by eliminating the need for regular dialysis treatments, fewer dietary restrictions, and potentially longer survival rates for eligible candidates.

Types of Kidney Donors

• Living donors can be related (living-related) or unrelated (living-unrelated) to the recipient. Living donor kidneys generally have better outcomes with longer graft survival rates and immediate function post-transplant.
• Deceased donors (formerly called cadaveric donors) are individuals who have been declared brain dead and whose families have consented to organ donation. These kidneys may experience delayed graft function and have slightly lower long-term survival rates compared to living donor kidneys.

Recipient Evaluation

• Comprehensive evaluation includes assessment of cardiovascular status, infectious disease screening, cancer screening, and psychosocial evaluation to determine candidacy. Patients with active malignancy, severe cardiovascular disease, or active infection are typically not candidates until these conditions are resolved.
• Laboratory testing includes tissue typing for human leukocyte antigen (HLA) matching, panel reactive antibody (PRA) screening, and crossmatching to determine compatibility between donor and recipient.

Donor Evaluation

• Living donors undergo extensive medical, psychological, and laboratory evaluations to ensure they are healthy enough to donate and will not experience significant health consequences from donation. This includes renal function testing, cardiovascular assessment, and screening for conditions that might affect kidney health.
• Deceased donor kidneys are evaluated for viability based on donor medical history, cause of death, age, and cold ischemia time (time from procurement to transplantation).

Immediate Pre-Transplant Care

• Prior to surgery, the recipient undergoes dialysis if needed, receives immunosuppressive induction therapy, and undergoes final crossmatch testing to confirm compatibility. Antibiotics are administered prophylactically to prevent surgical site infections.
• The anesthesia team performs a comprehensive assessment focusing on fluid status, electrolyte balance, and cardiovascular stability, as these patients often have multiple comorbidities.

Surgical Procedure

1. Recipient is placed under general anesthesia and positioned supine.
2. A hockey-stick or curvilinear incision is made in the lower abdomen (usually right side).
3. The donor kidney is placed in the extraperitoneal iliac fossa.
4. Vascular anastomoses are created: renal artery to iliac artery and renal vein to iliac vein.
5. Ureter is implanted into the bladder (ureteroneocystostomy) to establish urinary drainage.
6. A stent may be placed in the ureter to prevent stricture and is typically removed 4-6 weeks post-transplant.
7. The incision is closed and drains may be placed.

Immediate Post-Operative Nursing Care

• Intensive monitoring of vital signs, fluid status, urine output, and laboratory values is essential in the immediate post-operative period. Hourly urine output measurements help assess graft function, with output typically >100 mL/hour initially due to post-ischemic diuresis.
• Pain management, prevention of infection, monitoring for surgical complications, and administration of immunosuppressive medications are key nursing responsibilities. Daily weights and strict intake and output monitoring are crucial for fluid management.

Immunosuppression Regimens

• Standard maintenance immunosuppression typically consists of a triple-drug regimen including a calcineurin inhibitor (tacrolimus or cyclosporine), an antiproliferative agent (mycophenolate mofetil), and corticosteroids. This combination targets different pathways in the immune response to prevent rejection.
• Drug levels must be carefully monitored as these medications have narrow therapeutic windows and significant side effects. Tacrolimus levels are typically maintained between 8-12 ng/mL in the early post-transplant period and 5-8 ng/mL later.

Monitoring Graft Function

• Serum creatinine and blood urea nitrogen (BUN) are monitored daily initially, then with decreasing frequency as the patient stabilizes. A rising creatinine is the most sensitive indicator of potential rejection or other complications affecting graft function.
• Ultrasound is used to assess vascular flow, urine outflow, and to rule out complications such as obstruction, collections, or vascular thrombosis. Renal biopsy remains the gold standard for diagnosing rejection and is typically performed when there is unexplained deterioration in renal function.

Rejection

• Hyperacute rejection occurs within minutes to hours of transplantation due to preformed antibodies against donor antigens. It is rare with modern crossmatching techniques but is characterized by immediate graft failure requiring nephrectomy.
• Acute rejection typically occurs within the first 6 months post-transplant and is characterized by fever, graft tenderness, decreased urine output, and rising creatinine. It is treated with high-dose corticosteroids or T-cell depleting agents.
• Chronic rejection develops slowly over months to years and is characterized by gradual decline in renal function. It results from antibody-mediated damage and interstitial fibrosis/tubular atrophy (IFTA) and has limited treatment options.

Surgical Complications

• Vascular complications include renal artery stenosis, renal vein thrombosis, and arterial thrombosis. Arterial thrombosis is a surgical emergency requiring immediate intervention to save the graft.
• Urologic complications include urine leak, ureteral obstruction, and stricture. These may present with decreased urine output, increased creatinine, fluid collections, or hydronephrosis on imaging.
• Lymphocele is a collection of lymphatic fluid that can compress the ureter or vascular structures, potentially compromising graft function. Treatment ranges from observation to percutaneous drainage or surgical marsupialization.

Infections

• Transplant recipients are at increased risk for infections due to immunosuppression, with the type of infection following a typical timeline: bacterial infections predominate in the first month, opportunistic infections (CMV, PCP, fungal) from 1-6 months, and community-acquired infections after 6 months.
• Cytomegalovirus (CMV) is one of the most common opportunistic infections, especially in CMV-negative recipients who receive organs from CMV-positive donors. Prophylaxis with valganciclovir is typically given for 3-6 months post-transplant.

Medication Adherence

• Non-adherence to immunosuppressive medications is a leading cause of graft loss, particularly in adolescents and young adults. Nurses play a crucial role in education about the importance of medication adherence and helping patients develop strategies to maintain adherence.
• Strategies to improve adherence include pillboxes, medication alarms, smartphone apps, simplifying regimens when possible, and addressing barriers such as cost, side effects, and psychosocial factors.

Long-Term Complications

• Cardiovascular disease is the leading cause of death in kidney transplant recipients. Risk factors include pre-existing cardiovascular disease, hypertension, diabetes, dyslipidemia, and the effects of immunosuppressive medications.
• Malignancy risk is increased 2-3 fold compared to the general population, with skin cancers being most common, followed by post-transplant lymphoproliferative disorder (PTLD). Regular cancer screening is essential.
• Metabolic complications include new-onset diabetes after transplant (NODAT), hyperlipidemia, obesity, and osteoporosis. These are often related to immunosuppressive medications, particularly corticosteroids and calcineurin inhibitors.

Health Maintenance

• Regular follow-up with the transplant team is essential for monitoring graft function, adjusting immunosuppression, and screening for complications. Initially, visits are frequent (weekly to monthly) but may decrease to every 3-6 months once stable.
• Preventive health measures include recommended vaccinations (avoiding live vaccines), cancer screenings, bone density testing, and cardiovascular risk reduction. Patients should receive inactivated influenza vaccine annually and pneumococcal vaccination.

• Kidney transplantation is the preferred treatment for ESRD, offering better quality of life and survival compared to dialysis. The procedure involves placing a donor kidney in the iliac fossa while typically leaving native kidneys in place.
• Comprehensive pre-transplant evaluation includes assessment of cardiovascular status, infectious disease screening, cancer screening, and psychosocial evaluation. Contraindications include active infection, recent malignancy, and severe cardiovascular disease.
• Immunosuppression typically follows a triple-drug regimen with a calcineurin inhibitor, antiproliferative agent, and corticosteroids. Medication adherence is critical for graft survival.
• Post-transplant complications include rejection (hyperacute, acute, chronic), surgical complications (vascular, urologic), infections, and long-term issues (cardiovascular disease, malignancy, metabolic complications).
• Long-term management focuses on medication adherence, monitoring for complications, and preventive health measures including appropriate vaccinations and cancer screenings.

Memory Aids

Common Pitfalls

• Assuming all increases in creatinine are rejection. Remember to consider other causes: dehydration, medication toxicity, obstruction, infection.
• Focusing only on the transplanted kidney. Transplant recipients need comprehensive care including cardiovascular risk management, cancer screening, and bone health.
• Overlooking drug interactions. Many common medications interact with immunosuppressants, potentially leading to toxicity or subtherapeutic levels.
• Administering live vaccines. Always verify vaccine type before administration to transplant recipients.
• Discontinuing immunosuppressants during infection. While doses may need adjustment, abrupt discontinuation can trigger rejection.

Quick Check Questions